According to Baihua Pharmaceutical's announcement, the cumulative deviation value of the company's stock closing price drop for three consecutive trading days reached 20%, which is an abnormal fluctuation in stock trading. In the first half of 2026, the company achieved operating income of 157 million yuan, a year-on-year decrease of 22.13%; net profit to mother of 147.603 million yuan, a year-on-year decrease of 42.08%; deducted non-net profit of 12.1863 million yuan, a year-on-year decrease of 49.35%. In the second quarter of 2026, revenue increased 34.22% month-on-month, and net profit to mother increased 22.20% month-on-month. There have been no major changes in the company's main business, and there is no major change in innovative drug research and development. The latest rolling price-earnings ratio is 169.27 times, which is significantly higher than the industry level, and there is a risk of a rapid decline. After verification, the company and controlling shareholders had no material information that should have been disclosed but not disclosed.

According to Baihua Pharmaceutical's announcement, the cumulative deviation value of the company's stock closing price drop for three consecutive trading days reached 20%, which is an abnormal fluctuation in stock trading. In the first half of 2026, the company achieved operating income of 157 million yuan, a year-on-year decrease of 22.13%; net profit to mother of 147.603 million yuan, a year-on-year decrease of 42.08%; deducted non-net profit of 12.1863 million yuan, a year-on-year decrease of 49.35%. In the second quarter of 2026, revenue increased 34.22% month-on-month, and net profit to mother increased 22.20% month-on-month. There have been no major changes in the company's main business, and there is no major change in innovative drug research and development. The latest rolling price-earnings ratio is 169.27 times, which is significantly higher than the industry level, and there is a risk of a rapid decline. After verification, the company and controlling shareholders had no material information that should have been disclosed but not disclosed.